Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Moodys
Colorcon
Boehringer Ingelheim
Medtronic

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Patent: 5,792,838

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 5,792,838
Title: Method for stabilizing immunoglobulin compositions
Abstract:The invention relates to a stabilised immunoglobulin composition comprising at least one immunoglobulin together with a stabilising amount of a chelator of copper ions such as EDTA or citrate. Preferably the immunoglobulin is an antibody, for example a recombinant CDR-grafted antibody against the CDw52 antigen, most preferably CAMPATH-1H. The invention also relates to a process for enhancing the stability of an immunoglobulin which comprises subjecting the immunoglobulin to a purification procedure capable of removing copper ions therefrom. Preferably the immunoglobulin is rendered substantially free from detectable copper ions, for example on atomic absorption spectroscopy.
Inventor(s): Smith; Marjorie (Beckenham, GB3), Riveros-Rojas; Valentina (Beckenham, GB3)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:08/465,319
Patent Claims:see list of patent claims

Details for Patent 5,792,838

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial Glaxo Wellcome Inc. (Research Triangle Park, NC) 2015-08-11 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Glaxo Wellcome Inc. (Research Triangle Park, NC) 2015-08-11 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Glaxo Wellcome Inc. (Research Triangle Park, NC) 2015-08-11 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Boehringer Ingelheim
Johnson and Johnson
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.